ArticleJournal of nanobiotechnology2016
Inhibition of breast cancer with transdermal tamoxifen-encapsulated lipoplex.
Article in Journal of nanobiotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Design-ExpertPharmaceutics · 2026Article
- Synergistic anticancer effects of lipoplex-encapsulated Q7 peptide and doxorubicin against endometrial cancer cells.Scientific reports · 2026Article
- Liposomal Nanocarriers to Enhance Skin Delivery of Chemotherapeutics in Cancer Therapy.Bioengineering (Basel, Switzerland) · 2025Review
- A landscape of recent advances in lipid nanoparticles and their translational potential for the treatment of solid tumors.Bioengineering & translational medicine · 2024Review
- A flexible liposomal polymer complex as a platform of specific and regulable immune regulation for individual cancer immunotherapy.Journal of experimental & clinical cancer research : CR · 2023Article
- Mineral medicine: from traditional drugs to multifunctional delivery systems.Chinese medicine · 2022Review
- Lipid Nanoparticulate Drug Delivery Systems: Recent Advances in the Treatment of Skin Disorders.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Transdermal Delivery of Chemotherapeutics: Strategies, Requirements, and Opportunities.Pharmaceutics · 2021Review
- Enhanced anticancer activity and endocytic mechanisms by polymeric nanocarriers of n-butylidenephthalide in leukemia cells.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Article
- Enhancement of cytotoxicity and induction of apoptosis by cationic nano-liposome formulation ofInternational journal of medical sciences · 2021Article
- Positively Charged Nanoparticle Delivery of n-Butylidenephthalide Enhances Antitumor Effect in Hepatocellular Carcinoma.BioMed research international · 2021Article
- Antitumor Effects ofMolecules (Basel, Switzerland) · 2020Article
- Novel Tamoxifen Nanoformulations for Improving Breast Cancer Treatment: Old Wine in New Bottles.Molecules (Basel, Switzerland) · 2020Review
- EncapsulatedInternational journal of nanomedicine · 2020Article
- Antitumor Effect ofMolecules (Basel, Switzerland) · 2018Article
- A review on current nanomaterials and their drug conjugate for targeted breast cancer treatment.International journal of nanomedicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTamoxifen is currently used for the treatment of both early and advanced estrogen receptor (ER) positive breast cancer in pre- and post-menopausal women. However, using tamoxifen routinely to inhibit endogenous or exogenous estrogen effects is occasionally difficult because of its potential side effects.
objectivesThe aim of this study is to design a local drug delivery system to encapsulate tamoxifen for observing their efficacy of skin penetration, drug accumulation and cancer therapy.
methodsA cationic liposome-PEG-PEI complex (LPPC) was used as a carrier for the encapsulation of tamoxifen and forming 'LPPC/TAM' for transdermal release. The cytotoxicity of LPPC/TAM was analyzed by MTT. The skin penetration, tumor growth inhibition and organ damages were measured in xenograft mice following transdermal treatment.
resultsLPPC/TAM had an average size less than 270 nm and a zeta-potential of approximately 40 mV. LPPC/TAM displayed dramatically increased the cytotoxic activity in all breast cancer cells, especially in ER-positive breast cancer cells. In vivo, LPPC drug delivery helped the fluorescent dye penetrating across the skim and accumulating rapidly in tumor area. Administration of LPPC/TAM by transdermal route inhibited about 86 % of tumor growth in mice bearing BT474 tumors. This local treatment of LPPC/TAM did not injury skin and any organs.
conclusionLPPC-delivery system provided a better skin penetration and drug accumulation and therapeutic efficacy. Therefore, LPPC/TAM drug delivery maybe a useful transdermal tool of drugs utilization for breast cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.